Stocktoria
Mereo BioPharma Group plc MREO
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-06-09
Mereo BioPharma Group plc statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating margin | -8021.4% | — | -284.2% | — |
| Net margin | -8375.6% | — | -294.7% | — |
| FCF margin | -6198.2% | — | -211.3% | — |
| Return on assets | -91.2% | -56.6% | -44.3% | -54.5% |
| Return on equity | -102.4% | -70.9% | -58.3% | -82.1% |
| Current ratio | 10.46 | 5.40 | 6.72 | 3.09 |
| Revenue growth | — | -100.0% | — | — |
Source: SEC EDGAR filings · CIK 0001719714 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.